𝐏𝐮𝐛𝐥𝐢𝐜 𝐇𝐞𝐚𝐥𝐭𝐡 𝐖𝐚𝐫𝐧𝐢𝐧𝐠: 𝐍𝐀𝐅𝐃𝐀𝐂 𝐅𝐥𝐚𝐠𝐬 𝐒𝐮𝐛𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝 𝐀𝐬𝐭𝐚𝐦𝐨𝐜𝐢𝐥, 𝐀𝐬𝐭𝐚𝐦𝐞𝐧𝐭𝐢𝐧 𝐒𝐮𝐬𝐩𝐞𝐧𝐬𝐢𝐨𝐧𝐬 𝐢𝐧 𝐍𝐢𝐠𝐞𝐫𝐢𝐚

The National Agency for Food and Drugs Administration and Control, NAFDAC is notifying the public of the recall of two products: Astamocil (Amoxicillin Suspension 125mg/5ml) Batch 826024, and Astamentin (Amoxicillin/Clavulanic Acid Suspension 228.5 mg) Batches 0503024 and 0501724, manufactured by Sam-Ace Ltd in Nigeria.

The products were discovered by the agency following a recent Risk-Based Post-Marketing Surveillance conducted in the Coordinated Wholesale Centre (CWC) in Kano.

Laboratory investigation carried out on the products showed that both suspensions failed laboratory analysis due to low API content. The company has therefore been directed to recall the failed batches of the products from circulation.

According to the Agency, AMOXICILLIN is a penicillin-class antibacterial indicated for the treatment of infections due to susceptible strains of designated microorganisms. Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract.

It further explained that Amoxicillin and Clavulanic Acid is a combination prescription antibiotic. Amoxicillin is a penicillin antibiotic that fights bacteria in the body, as mentioned earlier. Clavulanic acid is a beta-lactamase inhibitor that helps prevent certain bacteria from becoming resistant to amoxicillin.

Amoxicillin and Clavulanic Acid are used to treat many different infections caused by bacteria, such as sinusitis, pneumonia, ear infections, bronchitis, urinary tract infections, and skin infections. 

NAFDAC further advised Healthcare professionals and consumers to report any suspicion of the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office, call 0800-162-3322, or send an email to sf.alert@nafdac.gov.ng